Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AFM11 |
Synonyms | |
Therapy Description |
AFM11 is a bi-specific antibody that targets CD19 and CD3, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 25875246, PMID: 31090657). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFM11 | AFM-11 | CD19 Antibody 21 CD3 Antibody 99 | AFM11 is a bi-specific antibody that targets CD19 and CD3, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 25875246, PMID: 31090657). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | POL | DEU | CZE | 0 |